^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Fallopian Tube Cancer |
| Drug: | Aybintio (bevacizumab biosimilar) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer...Aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer...
Secondary therapy:
carboplatin + paclitaxel; pegylated liposomal doxorubicin; topotecan; carboplatin + gemcitabine
